Panntherapi
Description
Panntherapi is a clinical stage French biotech company, laureate among others of the EIC Accelerator and i-Lab.
Panntherapi develops innovative drugs for chronic neurological diseases by acting on a new mechanism only activated under pathological conditions, allowing a better efficacy and a higher safety.
The first product (Phase 1 ongoing, EMA Scientific Advice and PIP submission done) is indicated for an orphan highly resistant epilepsy mostly paediatric: using post operative brain tissues from patients, still alive and having seizure ex vivo, and in a representative animal model of resistant epilepsy, our drug fully stops seizures in >80% of cases with no impact on other brain functions. Using our platform (AI, in vitro, ex vivo and in vivo models), we identified New Chemical Entities to treat other diseases of interest such as multiple sclerosis, chronic pain or psychiatric disorders.
Panntherapi is looking for a 5M€ funding at least to perform the 1st clinical trial in patients demonstrating the safety and dose effectiveness with our French partners and obtain preclinical proof of concept data for our 1st new lead by early 2026. Already followed by 5 pharmas, a deal is envisaged from 2026 or after the pivotal clinical trial in children in 2028.
Company members
Co-founders: Elsa Brillaud; Luc André Granier; Gilles Huberfeld; Nathalie Rouach